At a glance
ClinicalIndex Comparison RecordN/ACompleted· 774 enrolled
Drug / intervention
Ixazomibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NINLARO Capsules Drug Use-Results Survey (All-Case Surveillance) "Relapsed/Refractory Multiple Myeloma"
In Brief
An observational study evaluating Ixazomib for Relapsed/Refractory Multiple Myeloma. Completed, enrolled 774 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the safety of NINLARO in participants with relapsed/refractory multiple myeloma in daily clinical practice.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRelapsed/Refractory Multiple Myeloma
CountriesJapan
Collaborators--
Timeline
N/ACompletedFinished
201820192020202120222023202420252026
Enrollment StartMay 2017
First PostedMay 2017
Primary CompletionMar 2022
TodayJul 2026
First PostedMay 30, 2017
Enrollment StartMay 24, 2017
Primary CompletionMar 8, 2022
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 9.1 years ago
Interventions
Ixazomibdrug
Ixazomib capsules